Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C
A pan-cancer clinical platform to predict immunotherapy outcomes
Germline and Somatic Variants Co-Ocurrence Profile in Early Onset
Building a network of TP53 and IGHV testing reference centers
PDF) COVID-19 infection in adult patients with hematological
PET‐based radiomics signature can predict durable responses to CAR
Clara López Serrano - Clinical Trial Associate - Fortrea
Patricia Fernández Guzmán - PhD Student - Vall d'Hebron Institute
Young oncologists' perspective on the role and future of the
Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C
Haematologica. Volume 108, Issue 3 by Haematologica - Issuu
GROUP: Translational Control and Cancer Stem Cells in Colorectal